What adverse events have been reported with use of Rhophylac® for ITP?
A. Adverse reactions occurring during the treatment of ITP were evaluated in 98 Rho(D)-positive adults with chronic ITP who received a single dose of Rhophylac® 250 IU (50 mcg) per kg body weight. Adverse reactions that occurred in more than 10% of subjects were chills (35%), fever (25%), increase in bilirubin (21%), and headache (11%). All adverse reactions were mild to moderate in intensity with the exception of a case of severe headache. Signs of hemolysis were also observed.
